Rosuvastatin Dosing and Management in Adults
Start rosuvastatin at 10 mg once daily for most adults requiring moderate-intensity statin therapy, or 20-40 mg once daily for those requiring high-intensity therapy, with dose selection based on cardiovascular risk and LDL-C reduction goals. 1
Initial Dosing Strategy
The FDA-approved dosage range is 5-40 mg once daily, taken at any time of day with or without food 1. Your starting dose depends on the patient's cardiovascular risk category and target LDL-C reduction:
Standard Starting Doses by Indication:
High-intensity therapy (≥50% LDL-C reduction): Rosuvastatin 20-40 mg daily 2, 3
Moderate-intensity therapy (30-49% LDL-C reduction): Rosuvastatin 5-10 mg daily 2, 3
Important: Rosuvastatin is the most potent statin available—10 mg rosuvastatin provides similar LDL-C lowering to atorvastatin 20 mg or simvastatin 40 mg 4, 5.
Titration Protocol
Assess lipid response 4 weeks after initiation or dose adjustment 1. This is earlier than many clinicians wait, but allows for timely optimization.
- If LDL-C goal not achieved: Increase by one dose increment (typically 10 mg)
- Maximum dose: 40 mg daily (80 mg not recommended due to myopathy risk)
- Each doubling of dose provides approximately 6% additional LDL-C reduction 4, 5
For very high-risk patients not reaching goals on maximum statin therapy, add ezetimibe before increasing to 40 mg 2, 6.
Monitoring Parameters
Baseline (before starting):
- Complete lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
- ALT and AST
- Creatine kinase (CK) if symptomatic or high-risk for myopathy
- Creatinine/eGFR
Follow-up monitoring:
- Lipid panel: At 4-12 weeks, then every 3-12 months once stable 6, 3
- Liver enzymes: At 4 weeks after initiation, then as clinically indicated (routine monitoring no longer recommended) 3
- CK: Only if patient develops muscle symptoms—not routinely 3
Critical threshold: Stop therapy if ALT/AST >3× upper limit of normal or CK >10× upper limit of normal with symptoms 7.
Special Population Dosing Adjustments
Asian Patients:
Start at 5 mg daily due to 2-fold higher plasma concentrations 8, 1. Consider risks versus benefits if doses >20 mg needed. This is an FDA-mandated adjustment based on pharmacokinetic data showing significantly elevated drug levels in Asian populations.
Severe Renal Impairment (CrCl <30 mL/min, not on dialysis):
Start at 5 mg daily; do not exceed 10 mg daily 9, 1. No adjustment needed for mild-moderate renal impairment.
Drug Interactions Requiring Dose Limits:
- Cyclosporine: Maximum 5 mg daily 1
- Gemfibrozil: Avoid combination; if necessary, maximum 10 mg daily 1
- Protease inhibitors (atazanavir/ritonavir, lopinavir/ritonavir): Maximum 10 mg daily 1
- Multiple other interactions: See FDA label for complete list 1
Contraindications
Absolute contraindications:
- Active liver disease or unexplained persistent transaminase elevations
- Pregnancy and breastfeeding
- Hypersensitivity to rosuvastatin or any component
Relative contraindications/use with caution:
- History of statin-induced myopathy
- Hypothyroidism (treat first)
- Heavy alcohol use
- Age >75 years (weigh benefits versus risks, though continuation reasonable if already tolerating) 2
- Concomitant fibrate therapy (especially gemfibrozil)
Target LDL-C Goals by Risk Category
The 2018 AHA/ACC guidelines provide clear targets 2, 6, 3:
- Very high-risk ASCVD: <55 mg/dL (consider adding ezetimibe or PCSK9 inhibitor if not achieved) 2
- Established ASCVD: <70 mg/dL or ≥50% reduction from baseline 2, 6
- Diabetes age 40-75: ≥50% reduction with high-intensity statin if multiple risk factors 2
- Primary prevention (10-year risk ≥7.5%): ≥30% reduction (moderate-intensity) or ≥50% (high-intensity if risk ≥20%) 6
Common Pitfalls to Avoid
Don't start Asian patients at standard 10 mg dose—this FDA warning is frequently overlooked and increases myopathy risk 8, 1
Don't routinely monitor CK or liver enzymes—only check if symptomatic or clinically indicated 3
Don't combine with gemfibrozil—highest risk combination for myopathy; fenofibrate is safer alternative if fibrate needed 1
Don't underdose high-risk patients—rosuvastatin 5-10 mg provides only moderate-intensity therapy; use 20-40 mg for high-risk ASCVD 2, 3
Don't delay assessment beyond 4 weeks—early lipid monitoring allows prompt optimization 1